The U.S. Food and Drug Administration (FDA) has cleared Motilent's artificial intelligence (AI)-based gastrointestinal imaging software.
The company plans to roll out the software, called GIQuant, in partnership with Nuance Communications. It is used with MRI exams to measure and track the movement of the intestine; measuring this movement can help clinicians diagnose gastrointestinal conditions such as Crohn's disease.
